Format

Send to

Choose Destination
Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S37-40. doi: 10.1016/j.parkreldis.2015.09.021. Epub 2015 Sep 8.

New levodopa therapeutic strategies.

Author information

1
Department of Neurology, Henry Ford Hospital and Wayne State University School of Medicine, 6777 West Maple Road, West Bloomfield, MI 48322, USA. Electronic address: plewitt1@hfhs.org.

Abstract

During its almost half-century of use for treating Parkinson's disease, levodopa therapy has permitted most patients to reverse much of this disorder's symptomatology. However, the full range of its therapeutic properties is not completely understood, as levodopa is showing itself to be more than just a metabolic intermediate for dopamine synthesis. Improving the constancy of drug delivery is the next frontier for enhancing therapeutic options with levodopa. Because conventional immediate-release carbidopa-levodopa tablets yield such variable pharmacokinetic profiles (as do other marketed products attempting to extend levodopa effect), improved formulations are greatly needed by patients experiencing motor fluctuations. Products under development or recently released in the U.S. include intestinal infusion, sustained-release microtablets, gastric-retentive formulations, a levodopa pro-drug, and methods for delivery of the drug by inhalation or subcutaneous infusion.

KEYWORDS:

Drug delivery; Levodopa; Parkinson disease; Pharmacotherapy

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center